Personalis (PSNL) Q2 2024 earnings summary

Executive summary

• Achieved Q2 2024 revenue of $22.6 million, up 35% year-over-year, driven by 117% growth in biopharma/pharma tests and strong demand for MRD and tumor profiling products.

• Net loss narrowed to $12.8 million in Q2 2024 from $24.0 million in Q2 2023, reflecting higher revenue and cost reductions.

• Raised full-year 2024 revenue guidance to $79–81 million, reflecting continued momentum and increased demand.

• Strategic partnerships and commercialization agreements with Tempus and Moderna, and cross-license agreement with Myriad Genetics, are fueling commercial and clinical expansion.

• Settled IP litigation and entered a cross-license agreement with Myriad Genetics and Foresight Diagnostics, strengthening IP position and future royalty streams.

Financial highlights

• Q2 2024 revenue: $22.6 million, up from $16.7 million in Q2 2023; pharma testing/services revenue: $13.2 million, up 117%; enterprise revenue: $8.0 million, up 8%; population sequencing: $1.3 million, down 57%.

• Gross margin expanded to 35.6% from 28.7% year-over-year, driven by cost reductions and operating leverage.

• Operating expenses decreased to $24.9 million from $30.1 million year-over-year, mainly due to headcount reductions.

• Net loss for Q2 was $12.8 million, improved from $24 million in Q2 2023, including a $3 million non-cash gain from warrant revaluation.

• Cash and short-term investments at quarter-end were $87 million, with cash runway expected through Q1 2026.

Outlook and guidance

• Q3 2024 revenue expected in the range of $21–22 million.

• Full-year 2024 revenue guidance increased to $79–81 million, up from prior $76–78 million.

• Non-GAAP net loss for 2024 expected to be ~$75 million, improved from prior guidance.

• Cash usage for 2024 expected to be ~$60 million, down from previous $62 million guidance.

• Population sequencing revenue for 2024 expected at $8 million.